# EDGAR Filing Document

**Accession Number:** 0001048477
**File Stem:** 0001193125-25-173541
**Filing Date:** 2025-8
**Character Count:** 15656
**Document Hash:** c6171a6206a14a5462d73853bc891f55
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-173541.hdr.sgml**: 20250805

**ACCESSION NUMBER**: 0001193125-25-173541

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20250805

**DATE AS OF CHANGE**: 20250805

**EFFECTIVENESS DATE**: 20250805

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIOMARIN PHARMACEUTICAL INC
- **CENTRAL INDEX KEY:** 0001048477
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 680397820
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-289250
- **FILM NUMBER:** 251185127

**BUSINESS ADDRESS:**
- **STREET 1:** 105 DIGITAL DRIVE
- **CITY:** NOVATO
- **STATE:** CA
- **ZIP:** 94949
- **BUSINESS PHONE:** 4155066700

**MAIL ADDRESS:**
- **STREET 1:** 105 DIGITAL DRIVE
- **CITY:** NOVATO
- **STATE:** CA
- **ZIP:** 94949

**As filed with the Securities and Exchange Commission on August 5, 2025** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## BIOMARIN PHARMACEUTICAL INC.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **68-0397820** |
| **(State or other jurisdiction of**<br> **Incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**770 Lindaro Street** 

**San Rafael, CA 94901** 

**(Address of principal executive offices) (Zip code)** 

**BioMarin Pharmaceutical Inc. 2017 Equity Incentive Plan, as Amended April 1, 2025** 

**(Full title of the plan)** 

**G. Eric Davis** 

**Executive Vice President, Chief Legal Officer and Secretary** 

**BioMarin Pharmaceutical Inc.** 

**770 Lindaro Street** 

**San Rafael, California 94901** 

**(415) 506-6700** 

**(Name and address of agent for service) (Telephone number, including area code, of agent for service)** 

*Copies to:* 

**Chadwick Mills** 

**Siana E. Lowrey** 

**Cooley LLP** 

**3 Embarcadero Center** 

**20th Floor** 

**San Francisco, CA 94111-4004** 

**(415) 693-2000** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE** 

On May 20, 2025, the Registrant's stockholders approved an amendment to the BioMarin Pharmaceutical Inc. 2017 Equity Incentive Plan, as amended (the "2017 Plan") to increase the number of shares of Common Stock reserved for issuance under the 2017 Plan by 8,000,000 shares. Accordingly, this Registration Statement is being filed with the Securities and Exchange Commission (the "Commission") to register an additional 8,000,000 shares of Common Stock for future issuance under the 2017 Plan. These additional shares of Registrant's Common Stock are securities of the same class as other securities for which an original Registration Statement on Form S-8 was filed with the Commission on June 13, 2017 (File No. [333-218695](http://www.sec.gov/Archives/edgar/data/1048477/000119312517202493/d410495ds8.htm)) and subsequent Registration Statements on Form S-8 were filed with the Commission on October 16, 2019 (File No. [333-234231](http://www.sec.gov/Archives/edgar/data/1048477/000119312519268487/d823378ds8.htm)), February 17, 2022 (File No. [333-262824](http://www.sec.gov/Archives/edgar/data/1048477/000119312522045513/d295143ds8.htm)) and November 2, 2023 (File No. [333-275273)](http://www.sec.gov/Archives/edgar/data/1048477/000119312523269365/d561187ds8.htm) (collectively, the "Prior Registration Statements"). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Prior Registration Statements.

------

**PART II** 

---

| | |
|:---|:---|
| **ITEM 8.** | **EXHIBITS**  |

---

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** |  |
| 4.1 | [Restated Certificate of Incorporation of BioMarin Pharmaceutical Inc., previously filed with the Commission on June 12, 2017 as Exhibit 3.2 to the Registrant's Current Report on Form 8-K (File No. 000-26727), which is incorporated herein by reference](http://www.sec.gov/Archives/edgar/data/1048477/000119312517201414/d403853dex32.htm). |
| 4.2 | [Amended and Restated Bylaws of BioMarin Pharmaceutical Inc., previously filed with the Commission on March 3, 2025 as Exhibit 3.1 to the Company's Current Report on Form 8-K (File No. 000-26727), which is incorporated herein by reference](http://www.sec.gov/Archives/edgar/data/1048477/000119312525044103/d38831dex31.htm). |
| 5.1\* | [Opinion of Cooley LLP.](d949175dex51.htm) |
| 23.1\* | [Consent of KPMG LLP, independent registered public accounting firm.](d949175dex231.htm) |
| 23.2\* | [Consent of Cooley (included in Exhibit 5.1 to this Registration Statement on Form S-8).](d949175dex51.htm) |
| 24.1\* | [Power of Attorney (included on the signature page of this Registration Statement on Form S-8).](#sig) |
| 99.1 | [BioMarin Pharmaceutical Inc. 2017 Equity Incentive Plan, as amended on April 1, 2025, previously filed with the Commission on August 5, 2025 as Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025, which is incorporated herein by reference.](http://www.sec.gov/Archives/edgar/data/1048477/000104847725000090/bmrn-ex102x2017equityincen.htm) |
| 107\* | [Filing Fee Table.](d949175dexfilingfees.htm) |
| \* | Filed herewith |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Rafael, State of California, on August 5, 2025.

---

| | |
|:---|:---|
| **BIOMARIN PHARMACEUTICAL INC.** | **BIOMARIN PHARMACEUTICAL INC.** |
| By: | /s/ Brian R. Mueller |
|  | Brian R. Mueller |
|  | Executive Vice President and Chief Financial |
|  | Officer |

---

**POWER OF ATTORNEY** 

**KNOW ALL PERSONS BY THESE PRESENTS**, that each person whose signature appears below constitutes and appoints Alexander Hardy and Brian R. Mueller, and each or any one of them, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Alexander Hardy<br> Alexander Hardy | President and Chief Executive Officer<br> (*Principal Executive Officer*) | August 5, 2025 |
| /s/ Brian R. Mueller<br> Brian R. Mueller | Executive Vice President and Chief Financial Officer<br> (*Principal Financial Officer*) | August 5, 2025 |
| /s/ Erin Burkhart<br> Erin Burkhart | Group Vice President and Chief Accounting Officer<br> (*Principal Accounting Officer*) | August 5, 2025 |
| /s/ Richard A. Meier<br> Richard A. Meier | Chair of the Board of Directors | August 5, 2025 |
| /s/ Elizabeth McKee Anderson<br> Elizabeth McKee Anderson | Director | August 5, 2025 |
| /s/ Barbara W. Bodem<br> Barbara W. Bodem | Director | August 5, 2025 |

---

------

---

| | | |
|:---|:---|:---|
| /s/ Ian T. Clark<br> Ian T. Clark | Director | August 5, 2025 |
| /s/ Athena Countouriotis<br> Athena Countouriotis | Director | August 5, 2025 |
| /s/ Willard H. Dere<br> Willard H. Dere | Director | August 5, 2025 |
| /s/ Mark J. Enyedy<br> Mark J. Enyedy | Director | August 5, 2025 |
| /s/ Maykin Ho<br> Maykin Ho | Director | August 5, 2025 |
| /s/ Robert J. Hombach<br> Robert J. Hombach | Director | August 5, 2025 |
| /s/ Timothy P. Walbert<br> Timothy P. Walbert | Director | August 5, 2025 |

---

## Exhibit 5.1

**Exhibit 5.1**![LOGO](g949175g0802072948235.jpg)

Chadwick Mills

+1 650 843 5654

cmills@cooley.com

August 5, 2025

BioMarin Pharmaceutical Inc.

770 Lindaro Street

San Rafael, California 94901

Ladies and Gentlemen:

We have acted as counsel to BioMarin Pharmaceutical Inc., a Delaware corporation (the "***Company***"), and you have requested our opinion in connection with the filing by the Company of a registration statement on Form S-8 (the "***Registration Statement***") with the Securities and Exchange Commission (the "***Commission***") covering the offering of up to 8,000,000 shares (the "***Shares***") of its Common Stock, par value $0.001 per share, pursuant to the Company's 2017 Equity Incentive Plan, as amended (the "***Plan***").

In connection with this opinion, we have examined and relied upon (a) the Registration Statement and the related prospectus, (b) the Plan, (c) the Company's certificate of incorporation and bylaws, each as currently in effect, and (d) such other documents, records, certificates, memoranda and instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials and the due authorization, execution and delivery of all documents by all persons other than by the Company. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plan and the Registration Statement and the related prospectus, will be validly issued, fully paid, and nonassessable (except as to shares issued pursuant to deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

This opinion is limited to the matters expressly set forth in this letter, and no opinion should be implied, or may be inferred, beyond the matters expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof, and we have no obligation or responsibility to update or supplement this letter to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur.

Cooley LLP 3 Embarcadero Center 20th Floor San Francisco, CA 94111-4004

t: (415) 693-2000 f: (415) 693-2222 cooley.com

------

![LOGO](g949175g0802072948235.jpg)

August 5, 2025

Page Two

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Securities and Exchange Commission thereunder.

---

| | |
|:---|:---|
| Sincerely, | Sincerely, |
| **Cooley LLP** | **Cooley LLP** |
| By: | /s/ Chadwick Mills |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Chadwick Mills |

---

Cooley LLP 3 Embarcadero Center 20th Floor San Francisco, CA 94111-4004

t: (415) 693-2000 f: (415) 693-2222 cooley.com

## Exhibit 23.1

**Exhibit 23.1** 

**Consent of Independent Registered Public Accounting Firm** 

We consent to the use of our report dated February 24, 2025, with respect to the consolidated financial statements of BioMarin Pharmaceutical Inc., and the effectiveness of internal control over financial reporting, incorporated herein by reference.

/s/ KPMG LLP

San Francisco, California

August 5, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

#### Exhibit 107

#### Calculation of Filing Fee Table
Form S-8

(Form Type)

BioMarin Pharmaceutical Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

---

| | | | | |
|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;Security Type | Security<br>Class<br>Title | Maximum<br> Aggregate<br>Offering<br>Price | Fee<br>Rate | Amount of<br> Registration<br> Fee |
| &nbsp;&nbsp;&nbsp;Equity | Common Stock Other<sup>(</sup><sup>2)</sup>8000000<sup>(3)</sup>$58.94<sup>(2)</sup> | $471520000 | 0.0001531 | $72189.71 |
| &nbsp;&nbsp;&nbsp;Total Offering Amounts | &nbsp;&nbsp;&nbsp;Total Offering Amounts | $471520000 |  | $72189.71 |
| &nbsp;&nbsp;&nbsp;Total Fees Previously Paid | &nbsp;&nbsp;&nbsp;Total Fees Previously Paid |  |  |  |
| &nbsp;&nbsp;&nbsp;Total Fee Offsets | &nbsp;&nbsp;&nbsp;Total Fee Offsets |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Fee Due | &nbsp;&nbsp;&nbsp;Net Fee Due |  |  | $72189.71 |

---

(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of common stock ("Common Stock") of BioMarin Pharmaceutical Inc. (the "Registrant") that become issuable under the Registrant's 2017 Equity Incentive Plan, as Amended April 1, 2025 (the "2017 Plan") by reason of any stock dividend, stock split, recapitalization or other similar transaction effected that increases the number of outstanding shares of Common Stock.

(2) Estimated in accordance with Rule 457(h) and Rule 457(c) under the Securities Act. The price per share and aggregate offering price are based upon the average of the high and low prices of the Registrant's Common Stock on July 30, 2025 as reported on the Nasdaq Global Select Market.

(3) Represents additional shares of the Registrant's Common Stock reserved for future issuance under the Registrant's 2017 Plan.